Open AccessATP‑binding cassette transporter A1: A promising therapy target for prostate cancer (Review)
Author(s) -
Tao Xiong,
Gang Xu,
XueLong Huang,
Kaiqiang Lu,
Weiquan Xie,
Kai Yin,
Jian Tu
Publication year - 2017
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2017.1506
Subject(s) - abca1 , prostate cancer , tangier disease , cancer , cancer research , cholesterol , biology , prostate , atp binding cassette transporter , medicine , endocrinology , transporter , biochemistry , gene
ATP-binding cassette transporter A1 (ABCA1) has been found to mediate the transfer of cellular cholesterol across the plasma membrane to apolipoprotein A-I (apoA-I), and is essential for the synthesis of high-density lipoprotein. Mutations of the ABCA1 gene may induce Tangier disease and familial hypoalphalipoproteinemia; they may also lead to loss of cellular cholesterol homeostasis in prostate cancer, and increased intracellular cholesterol levels are frequently found in prostate cancer cells. Recent studies have demonstrated that ABCA1 may exert anticancer effects through cellular cholesterol efflux, which has been attracting increasing attention in association with prostate cancer. The aim of the present review was to focus on the current views on prostate cancer progression and the various functions of ABCA1, in order to provide new therapeutic targets for prostate cancer.